Safety and Pharmacokinetics of HRS-2261, a P2X3 Receptor Antagonist, in Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled Phase 1 Study

ConclusionsHRS-2261 demonstrated good tolerability, with a low incidence of dysgeusia. The PK profile was favorable. This study supports further development of HRS-2261 as a potential P2X3 receptor antagonist for chronic cough.Trial Registration NumberClinical trials.gov, identifier: NCT05274516. Trial registration date: March 10, 2022.
Source: Clinical Pharmacokinetics - Category: Drugs & Pharmacology Source Type: research